Concepedia

Publication | Closed Access

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma

DOI

113

Citations

13

References

2015

Year

Amit M. Oza, Sandro Pignata, Andrés Poveda, Mary McCormack, Andrew R. Clamp, Benjamin Schwartz, Jonathan D. Cheng, Xiaoyun Li, Kristy H. Campbell, P. Dodion,
Journal of Clinical Oncology

Abstract

Oral ridaforolimus shows encouraging activity in advanced endometrial cancer but is associated with significant toxicity. Inhibition of the PI3K/Akt/mTOR pathway may be a viable therapeutic target.

References

YearCitations

Page 1